STAAR Surgical (NASDAQ:STAA) Sees Positive Outlook and Upgrade

Company Overview - STAAR Surgical specializes in the development, manufacture, and marketing of implantable lenses for the eye, primarily used in refractive surgery to improve vision [1] - The company competes with other players in the ophthalmic industry, including Alcon and Bausch + Lomb [1] Stock Performance - As of the latest data, STAA is priced at $25.59, reflecting an increase of 8.71% or $2.05 [4] - The stock has shown significant volatility, with a trading range over the past year between $13.50 and $30.81 [6] - During the trading day, the stock fluctuated between a low of $25.09 and a high of $27.50 [4] Market Outlook - John Young from Canaccord Genuity has set a price target of $30.75 for STAA, indicating a potential increase of about 18.77% from its current price [2][6] - The stock has been upgraded to a Zacks Rank 2 (Buy), reflecting increased optimism about STAAR Surgical's earnings prospects [3][6] - STAAR Surgical has a market capitalization of approximately $1.27 billion, indicating its size in the market [5] - The trading volume for the day is 5.54 million shares, reflecting strong investor interest [5]